# Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

> **NCT00874848** · PHASE2 · COMPLETED · sponsor: **HiberCell, Inc.** · enrollment: 90 (actual)

## Conditions studied

- NSCLC

## Interventions

- **BIOLOGICAL:** Imprime PGG Injection
- **BIOLOGICAL:** Cetuximab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00874848
- **Lead sponsor:** HiberCell, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2012-11
- **Final completion:** 2015-08
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2016-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00874848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00874848, "Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00874848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*